MMR at 6 Months Trial

Summary

Randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the MMRvaxpro-vaccine administered at 6 months of age

Timeline

Start

2019-04-15

Primary completion

2022-01-07

Completion

2022-01-07

Publications

• Buus S, Vittrup DM, Schmidt JD, Jensen A, Stryhn A, Stensballe LG. Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial. Front Immunol. 2025 Mar 17;16:1546253. doi: 10.3389/fimmu.2025.1546253. eCollection 2025.
• Sorensen JK, Jensen A, Zimakoff AC, Vittrup DM, Malon M, Kim S, Hatley EV, Bybjerg-Grauholm J, Kaur S, Pociot F, Stensballe LG, Svensson J. Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children. Vaccine. 2025 Mar 19;50:126788. doi: 10.1016/j.vaccine.2025.126788. Epub 2025 Feb 5.
• Vittrup DM, Jensen A, Sorensen JK, Zimakoff AC, Malon M, Charabi S, Johansen MR, Simoes EAF, Kirkby NS, Buus S, Svensson J, Stensballe LG. Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants. EClinicalMedicine. 2024 Jan 12;68:102421. doi: 10.1016/j.eclinm.2023.102421. eCollection 2024 Feb.
• Zimakoff AC, Jensen A, Vittrup DM, Herlufsen EH, Sorensen JK, Malon M, Svensson J, Stensballe LG. Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial. BMJ. 2023 Jun 7;381:e072724. doi: 10.1136/bmj-2022-072724.

Drugs

Indications